AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug....

Zacks Investment Research - 6/17/2025 11:31:04 AM More News for ABBV
Stock Analysis for ABBV
Related Stocks: